Meet our CEO at LSX Nordic Conference on 6-17 September 2021

Read More

Enjoy Tara’s company presentation at Redeye Growth Day June 2

Read More

Read the article with CEO Tara Heitner and COO Malin Berthold telling the story how Cyxone initiated the Covid-19 trial

Read More

Cyxone – Creating early stage, innovative treatments with a difference

Treatments for diseases such as rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders have come a long way but still have several shortcomings. These include adverse side effects, administration forms that often require visits to the hospital, and poor response or resistance in some patients. Cyxone is a clinical-stage biotech company focusing on the development of treatments that are administered early stage, have fewer, less severe side effects, can be taken on an outpatient basis and are showing promising response in early clinical trials. To put it simply, Cyxone’s treatments will increase the quality of life for millions of people.

Our Drug Projects

Rheumatoid Arthritis (Rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Read More

Covid-19 (Rabeximod)

Inhibits the release of multiple cytokines without suppressing the general immune system

Read More

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Read More

CEO Tara Heitner comments

“Despite these challenges, our team has done a fantastic job to progress the Covid-19 trial, finding solutions to mitigate these challenging conditions in a professional way.”

Read More